256 related articles for article (PubMed ID: 29620999)
1. Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.
van Roon-Mom WMC; Roos RAC; de Bot ST
Nucleic Acid Ther; 2018 Apr; 28(2):59-62. PubMed ID: 29620999
[TBL] [Abstract][Full Text] [Related]
2. Targeting Huntingtin Expression in Patients with Huntington's Disease.
Tabrizi SJ; Leavitt BR; Landwehrmeyer GB; Wild EJ; Saft C; Barker RA; Blair NF; Craufurd D; Priller J; Rickards H; Rosser A; Kordasiewicz HB; Czech C; Swayze EE; Norris DA; Baumann T; Gerlach I; Schobel SA; Paz E; Smith AV; Bennett CF; Lane RM;
N Engl J Med; 2019 Jun; 380(24):2307-2316. PubMed ID: 31059641
[TBL] [Abstract][Full Text] [Related]
3. Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():57-67. PubMed ID: 32865782
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
[TBL] [Abstract][Full Text] [Related]
5. [Anti-sense oligonucleotides RNA therapy in Huntington disease: a great promise and many unknowns].
Durr A
Med Sci (Paris); 2019 Nov; 35(11):834-836. PubMed ID: 31845872
[No Abstract] [Full Text] [Related]
6. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
7. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
8. How the gene behind Huntington's disease could be neutralized.
Drew L
Nature; 2018 May; 557(7707):S39-S41. PubMed ID: 29844556
[No Abstract] [Full Text] [Related]
9. Nucleic Acid Therapeutics in Huntington's Disease.
Singh K; Roy I
Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
[TBL] [Abstract][Full Text] [Related]
10. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.
Rook ME; Southwell AL
BioDrugs; 2022 Mar; 36(2):105-119. PubMed ID: 35254632
[TBL] [Abstract][Full Text] [Related]
11. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
Leavitt BR; Kordasiewicz HB; Schobel SA
JAMA Neurol; 2020 Jun; 77(6):764-772. PubMed ID: 32202594
[TBL] [Abstract][Full Text] [Related]
12. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.
Aly AE; Caron NS; Black HF; Schmidt ME; Anderson C; Ko S; Baddeley HJE; Anderson L; Casal LL; Rahavi RSM; Martin DDO; Hayden MR
J Control Release; 2023 Aug; 360():913-927. PubMed ID: 37468110
[TBL] [Abstract][Full Text] [Related]
13. Huntingtin-lowering strategies for Huntington's disease.
Barker RA; Fujimaki M; Rogers P; Rubinsztein DC
Expert Opin Investig Drugs; 2020 Oct; 29(10):1125-1132. PubMed ID: 32745442
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
15. [Gene-selective treatment approaches for Huntington's disease].
Mühlbäck A; Lindenberg KS; Saft C; Priller J; Landwehrmeyer GB
Nervenarzt; 2020 Apr; 91(4):303-311. PubMed ID: 32179957
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the therapeutic development for Huntington disease.
Mestre TA
Parkinsonism Relat Disord; 2019 Feb; 59():125-130. PubMed ID: 30616867
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides for neurodegeneration.
Leavitt BR; Tabrizi SJ
Science; 2020 Mar; 367(6485):1428-1429. PubMed ID: 32217715
[No Abstract] [Full Text] [Related]
18. Hunting down huntingtin.
Aronin N; Moore M
N Engl J Med; 2012 Nov; 367(18):1753-4. PubMed ID: 23113488
[No Abstract] [Full Text] [Related]
19. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.
Skotte NH; Southwell AL; Østergaard ME; Carroll JB; Warby SC; Doty CN; Petoukhov E; Vaid K; Kordasiewicz H; Watt AT; Freier SM; Hung G; Seth PP; Bennett CF; Swayze EE; Hayden MR
PLoS One; 2014; 9(9):e107434. PubMed ID: 25207939
[TBL] [Abstract][Full Text] [Related]
20. Failure of genetic therapies for Huntington's devastates community.
Kwon D
Nature; 2021 May; 593(7858):180. PubMed ID: 33963316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
